- Previous Close
1,667.00 - Open
1,644.00 - Bid 1,633.00 x --
- Ask 1,638.00 x --
- Day's Range
1,567.00 - 1,659.00 - 52 Week Range
380.00 - 1,850.00 - Volume
3,256,600 - Avg. Volume
2,149,570 - Market Cap (intraday)
117.888B - Beta (5Y Monthly) 0.31
- PE Ratio (TTM)
-- - EPS (TTM)
-40.51 - Earnings Date Jun 11, 2025 - Jun 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1,320.00
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson's disease, spinal cord injury, and Alzheimer's disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
www.sanbio.comRecent News: 4592.T
View MorePerformance Overview: 4592.T
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4592.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4592.T
View MoreValuation Measures
Market Cap
120.05B
Enterprise Value
117.52B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
68.10
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-51.74%
Return on Equity (ttm)
-126.57%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-2.88B
Diluted EPS (ttm)
-40.51
Balance Sheet and Cash Flow
Total Cash (mrq)
2.92B
Total Debt/Equity (mrq)
22.52%
Levered Free Cash Flow (ttm)
-2.17B